MGC018
Phase 2Small molecule
MGC018 is one of 19 small molecule programs targeting Extensive-stage Small-cell Lung Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Extensive-Stage Small-Cell Lung Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Beyfortus
BeiGenePhase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Pumitamig
Bristol-Myers SquibbPhase 3
Imfinzi
AstraZenecaPhase 2
Tarlatamab-Dznl
AmgenPhase 2
BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
QL2107
Qilu Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MGC018. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGeorgetown University